KR940021051A - 3-step drug release sustained tablet - Google Patents
3-step drug release sustained tablet Download PDFInfo
- Publication number
- KR940021051A KR940021051A KR1019930003140A KR930003140A KR940021051A KR 940021051 A KR940021051 A KR 940021051A KR 1019930003140 A KR1019930003140 A KR 1019930003140A KR 930003140 A KR930003140 A KR 930003140A KR 940021051 A KR940021051 A KR 940021051A
- Authority
- KR
- South Korea
- Prior art keywords
- drug
- tablet
- release
- layer
- matrix layer
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
본 발명은 3단계로 약물을 방출하는 지속성 정제에 관한 것이다.The present invention relates to long-acting tablets that release the drug in three steps.
본 발명의 3단계 약물 방출형 지속성 정제는 초기에 신속한 약물용출작용을 나타내는 표피층, 그 이후 일정한 용출속도를 유지시키는 중간 매트릭스층 및 후기에 다시 신속한 약물용출작용을 나타내는 내부 핵층의 3층으로 구성되며, 각 층마다 일정한 양의 약물을 함유한다.The three-stage drug release sustained tablet of the present invention consists of an epidermal layer that initially exhibits rapid drug dissolution, an intermediate matrix layer that maintains a constant dissolution rate, and three layers of an inner nuclear layer that exhibit rapid drug dissolution again later. Each layer contains a certain amount of drug.
본 발명의 정제는 초기의 신속한 약물방출, 중기의 일정속도의 지속적 방출, 후기의 2차적인 신속한 방출에 이르는 3단계의 방출특성을 가짐으로써, 기존의 제제에 비하여 체내에서 신속히 유효혈중농도에 도달한 후 장시간 유효혈중농도를 유지할 수 있는 잇점이 있다.The tablet of the present invention has three stages of release characteristics, that is, rapid drug release in the early stage, continuous release at a constant rate in the middle stage, and secondary rapid release in the late stage, so that the effective blood concentration is rapidly reached in the body as compared with conventional formulations. There is an advantage that can maintain effective blood concentration after a long time.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
제2도는 본 발명에 의한 지속성 정제의 용출특성을 나타내며,2 shows the dissolution characteristics of the long-acting tablet according to the present invention,
제3도는 본 발명에 의한 지속성 정제의 pH에 따른 용출특성을 나타낸다.Figure 3 shows the dissolution characteristics of the sustained tablet according to the pH according to the present invention.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930003140A KR940021051A (en) | 1993-03-03 | 1993-03-03 | 3-step drug release sustained tablet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930003140A KR940021051A (en) | 1993-03-03 | 1993-03-03 | 3-step drug release sustained tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
KR940021051A true KR940021051A (en) | 1994-10-17 |
Family
ID=66912205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930003140A KR940021051A (en) | 1993-03-03 | 1993-03-03 | 3-step drug release sustained tablet |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR940021051A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100456933B1 (en) * | 1999-12-17 | 2004-11-10 | 르 라보레또레 쎄르비에르 | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
-
1993
- 1993-03-03 KR KR1019930003140A patent/KR940021051A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100456933B1 (en) * | 1999-12-17 | 2004-11-10 | 르 라보레또레 쎄르비에르 | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4863742A (en) | Controlled absorption pharmaceutical composition | |
AU672526B2 (en) | Bioadhesive pharmaceutical composition for the controlled release of active principles | |
US9867791B2 (en) | Method of administering amantadine prior to a sleep period | |
ATE66813T1 (en) | DRUG FORMULATION. | |
AR020610A1 (en) | USE OF A TYPE C METACRYLIC ACID COPOLYMER ACCORDING TO THE US NATIONAL FORMULARY USP / NF PHARMACOPEA, AS A DEGREGATION AGENT AND THE MANUFACTURING PROCEDURE OF A TABLET WITH SUCH COPOLYMER | |
KR890006226A (en) | New drugs and methods for their preparation | |
AU1607302A (en) | Pharmaceutical preparation comprising an active dispersed on a matrix | |
KR900009071A (en) | Adhesive film | |
KR880010759A (en) | Controlled release preparations | |
CA2136411A1 (en) | Immediate Release Tablet Cores of Insoluble Drugs Having Sustained Release Coating | |
KR20140030158A (en) | Methods and compositions for treatment of attention deficit disorder | |
JP2007532689A (en) | Particulate oral galenical formulation for delayed and controlled release of active pharmaceutical ingredients | |
TNSN98229A1 (en) | EXTENDED RELEASE ORAL PHARMACEUTICAL FORMULATION | |
WO2001080829A3 (en) | Taste masking coating composition | |
IE880281L (en) | Swellable pellets | |
AU2002221939A1 (en) | Rapidly disintegrating tablet comprising an acid-labile active ingredient | |
AR013117A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES A BENZOFURAN DERIVATIVE WITH ANTIARRHYTHMIC ACTIVITY ADAPTED FOR ORAL ADMINISTRATION | |
KR840006765A (en) | Process for preparing sustained release solid dosage forms | |
KR100583065B1 (en) | Multiparticulate pharmaceutical form with programmed and timed release and preparation method | |
KR940021051A (en) | 3-step drug release sustained tablet | |
BG101884A (en) | Salts of the clavulanic acid | |
JP2002512946A5 (en) | ||
JPS6440423A (en) | Patch for mucosa in oral cavity | |
EP0334014A3 (en) | Substitued imidazolinones and imidazolethiones | |
Pearson et al. | Studies on membrane-active vaginal spermicides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Withdrawal due to no request for examination |